Cargando…

Therapeutic Options for Visceral Leishmaniasis

Visceral leishmaniasis (VL), also known as Kala-Azar, is a disseminated protozoal infection caused principally by Leishmania donovani and Leishmania infantum (known as Leishmania chagasi in South America). The therapeutic options for VL are diverse and depend on different factors, such as the geogra...

Descripción completa

Detalles Bibliográficos
Autores principales: Monge-Maillo, Begoña, López-Vélez, Rogelio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3837193/
https://www.ncbi.nlm.nih.gov/pubmed/24170666
http://dx.doi.org/10.1007/s40265-013-0133-0
_version_ 1782292410413350912
author Monge-Maillo, Begoña
López-Vélez, Rogelio
author_facet Monge-Maillo, Begoña
López-Vélez, Rogelio
author_sort Monge-Maillo, Begoña
collection PubMed
description Visceral leishmaniasis (VL), also known as Kala-Azar, is a disseminated protozoal infection caused principally by Leishmania donovani and Leishmania infantum (known as Leishmania chagasi in South America). The therapeutic options for VL are diverse and depend on different factors, such as the geographical area of the infection, development of resistance to habitual treatments, HIV co-infection, malnourishment and other concomitant infections. This article provides an exhaustive review of the literature regarding studies published on the treatment of VL, and gives therapeutic recommendations stratified according to their level of evidence, the species of Leishmania implicated and the geographical location of the infection.
format Online
Article
Text
id pubmed-3837193
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-38371932013-11-29 Therapeutic Options for Visceral Leishmaniasis Monge-Maillo, Begoña López-Vélez, Rogelio Drugs Review Article Visceral leishmaniasis (VL), also known as Kala-Azar, is a disseminated protozoal infection caused principally by Leishmania donovani and Leishmania infantum (known as Leishmania chagasi in South America). The therapeutic options for VL are diverse and depend on different factors, such as the geographical area of the infection, development of resistance to habitual treatments, HIV co-infection, malnourishment and other concomitant infections. This article provides an exhaustive review of the literature regarding studies published on the treatment of VL, and gives therapeutic recommendations stratified according to their level of evidence, the species of Leishmania implicated and the geographical location of the infection. Springer International Publishing 2013-10-30 2013 /pmc/articles/PMC3837193/ /pubmed/24170666 http://dx.doi.org/10.1007/s40265-013-0133-0 Text en © The Author(s) 2013 https://creativecommons.org/licenses/by-nc/2.5/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Review Article
Monge-Maillo, Begoña
López-Vélez, Rogelio
Therapeutic Options for Visceral Leishmaniasis
title Therapeutic Options for Visceral Leishmaniasis
title_full Therapeutic Options for Visceral Leishmaniasis
title_fullStr Therapeutic Options for Visceral Leishmaniasis
title_full_unstemmed Therapeutic Options for Visceral Leishmaniasis
title_short Therapeutic Options for Visceral Leishmaniasis
title_sort therapeutic options for visceral leishmaniasis
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3837193/
https://www.ncbi.nlm.nih.gov/pubmed/24170666
http://dx.doi.org/10.1007/s40265-013-0133-0
work_keys_str_mv AT mongemaillobegona therapeuticoptionsforvisceralleishmaniasis
AT lopezvelezrogelio therapeuticoptionsforvisceralleishmaniasis